Announcing Webinar to Shed New Light on Treatment for Dry Eye Sufferers

Share Article

TearScience Webinar to take Place Wednesday, November 19, 2014 at 1 PM EST

TearScience and will be conducting a webinar on November 19th, 2014 from 1:00 to 1:30 pm EST that will provide enlightening information on the root cause of roughly 90% of dry eye. Millions suffer from dry eye across the world but recent research has shown that the majority of those who have been diagnosed with dry eye most likely suffer from Meibomian Gland Dysfunction (MGD) and it is treatable.

The webinar will explain how essential oils produced by the Meibomian glands in the eyelids can become blocked. When these glands are blocked, the needed oils are not sufficiently produced and the protective watery layer in the eyes evaporates. This is what causes the sensation of scratchy, tired and irritated eyes associated with dry eye. Dr. Arthur Epstein, one of the nation’s foremost experts on dry eye, will conduct the webinar and will provide informative insight about Meibomian Gland Dysfunction (MGD) and modern treatments that are available today. Mr. Tim Willis, CEO of TearScience, the pioneering company who developed LipiFlow Treatment, will also participate.

The webinar will last approximately 20 minutes and there will be 10 minutes for direct questions. All those who attend the webinar and take a short survey afterwards will receive a $100 voucher good towards a LipiFlow treatment. TearScience Inc. is presenting the Webinar in association with

Learn more about the webinar and register at:

For more information about LipiFlow, please visit

About TearScience
TearScience is a medical device company that pioneers breakthrough technologies to significantly improve identification, diagnosis, and treatment of Meibomian Gland Dysfunction (MGD). MGD, the leading cause of dry eye, is chronic and progressive and affects approximately 300 million people worldwide. The TearScience® Solution for MGD is a comprehensive in-office diagnosis and treatment solution that includes the LipiView®, the Korb Meibomian Gland Evaluator™, and the LipiFlow® Thermal Pulsation System. It is FDA-cleared and has been clinically proven to improve outcomes in patients with MGD. For additional information on how TearScience® is improving gland function and alleviating symptoms for patients with MGD worldwide, please visit

Media Contact
Tiffany Harwell
919-747-4990 Ext. 406

TearScience and LipiFlow are registered trademarks of TearScience Inc.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Scott Yates
OnPoint Communications
+1 919-649-6621
Email >